Low-risk patients have an enrichment of antigen processing and presentation, NK cell-mediated cytotoxicity, T cell receptor, and chemokine signaling pathways. Also, these patients have a high proportion of tumor-infiltrating CD8+ T cells, activated NK cells, and M1 macrophages and high expression of PD1, PDL1, CTLA-4, LAG3, and TIGIT. The gene discussed is CD274; the disease is neoplasm.